Invex Therapeutics Ltd

IXC

AU0000048621

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 20:45:48 2024-09-09 EDT			5-day change	1st Jan Change
0.0710 ^AUD	+1.43%		+1.43%	-12.35%

08-22	Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2024	CI
03-20	Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Invex Therapeutics Ltd

Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2024	08-22	CI
Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	03-19	MT
Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses	02-15	MT
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-15	CI
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	12-21	MT
Invex Therapeutics to Secure European Patent Grant for Neurological Medication	11-21	MT
Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director	11-08	CI
Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-17	CI
Invex Therapeutics Ltd Announces Board Changes	23-07-02	CI
Invex Therapeutics Jumps 19% After Securing Second European Orphan Drug Designation for Exenatide	23-06-22	MT
Invex Therapeutics Secures Approval for IIH EVOLVE Phase III Trial in France; Shares Rise 7%	23-04-20	MT
Israel's Ministry of Health Approves Invex Therapeutics' IIH EVOLVE Clinical Trial	23-04-19	MT
Invex Therapeutics Secures Clearance for Phase 2 Neurological Trial in Germany; Shares Rise 4%	23-03-19	MT
Invex Therapeutics Ltd Announces the Approval to Commence the IIH EVOLVE Phase III Clinical Trial	23-03-19	CI
Invex Therapeutics Ltd. Announces the Publication of the Invex Phase II 'Pressure' Clinical Trial	23-03-13	CI
Invex Therapeutics More Than Doubles Fiscal H1 Loss	23-02-17	MT
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-16	CI
Invex Therapeutics Opens First US Clinical Trial Site in Texas	23-01-19	MT
Invex Therapeutics Ltd Announces First US Clinical Site Activated in IIH Evolve Phase III Clinical Trial	23-01-18	CI
Invex Therapeutics Gains European Regulator Approval for Pediatric Plan	22-12-13	MT
Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA	22-12-13	CI
Invex Therapeutics Secures Regulatory, Ethics Approval for Phase 3 Neurological Trial in New Zealand	22-11-25	MT
Invex Therapeutics Ltd Announces Approval to Commence the IIH EVOLVE Phase III Clinical Trial Received from the New Zealand Medicines and Medical Devices Safety Authority	22-11-24	CI
Invex Therapeutics Doses First Patient in Phase 3 Neurological Trial; Shares Rise 5%	22-11-20	MT
Invex Therapeutics Ltd Announces First Patient Randomised in Iih Evolve Phase Iii Trial	22-11-20	CI

Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. It has completed a Phase II trial. The Companyâs lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The Company is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-02-12 - Q2 2025 Earnings Release (Projected)

More about the company